Perspectives in immunotherapy: Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

Paolo A. Ascierto; Carlo Bifulco; Luigi Buonaguro; Leisha A. Emens; Robert L. Ferris; Bernard A. Fox; Greg M. Delgoffe; Jérôme Galon; Cesare Gridelli; Marco Merlano; Paul Nathan; Kunle Odunsi; Hideho Okada; Chrystal M. Paulos; Sandro Pignata; Kurt A. Schalper; Stefani Spranger; Giampaolo Tortora; Hassane Zarour; Lisa H. Butterfield; Igor Puzanov

doi:10.1186/s40425-019-0798-3

Perspectives in immunotherapy: Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

Paolo A. Ascierto
, Carlo Bifulco
, Luigi Buonaguro
, Leisha A. Emens
, Robert L. Ferris
, Bernard A. Fox
, Greg M. Delgoffe
, Jérôme Galon
, Cesare Gridelli
, Marco Merlano
, Paul Nathan
, Kunle Odunsi
, Hideho Okada
, Chrystal M. Paulos
, Sandro Pignata
, Kurt A. Schalper
, Stefani Spranger
, Giampaolo Tortora
, Hassane Zarour
, Lisa H. Butterfield

Igor Puzanov

Medicine

University at Buffalo

IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
Robert W. Franz Cancer Research Center
University of Pittsburgh
Translational Molecular Pathology
Institut national de la santé et de la recherche médicale
Azienda Ospedaliera S.G. Moscati
S. Croce General Hospital
East and North Hertfordshire NHS Trust
Roswell Park Cancer Institute
University of California at San Francisco
Medical University of South Carolina
Yale University
Massachusetts Institute of Technology
Fondazione Policlinico Universitario A. Gemelli IRCCS

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.

Original language	English
Article number	332
Journal	Journal for ImmunoTherapy of Cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40425-019-0798-3
State	Published - Nov 29 2019

Keywords

Biomarkers
Checkpoint inhibitors
Combination therapy
Immunotherapy
Tumor microenvironment

Access to Document

10.1186/s40425-019-0798-3

Cite this

Ascierto, P. A., Bifulco, C., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M., Nathan, P., Odunsi, K., Okada, H., Paulos, C. M., Pignata, S., Schalper, K. A., Spranger, S., Tortora, G., Zarour, H., ... Puzanov, I. (2019). Perspectives in immunotherapy: Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). Journal for ImmunoTherapy of Cancer, 7(1), Article 332. https://doi.org/10.1186/s40425-019-0798-3

@article{56a3a1ddfeef45ea914f0678d1687742,

title = "Perspectives in immunotherapy: Meeting report from the {"}immunotherapy Bridge 2018{"} (28-29 November, 2018, Naples, Italy)",

abstract = "Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.",

keywords = "Biomarkers, Checkpoint inhibitors, Combination therapy, Immunotherapy, Tumor microenvironment",

author = "Ascierto, \{Paolo A.\} and Carlo Bifulco and Luigi Buonaguro and Emens, \{Leisha A.\} and Ferris, \{Robert L.\} and Fox, \{Bernard A.\} and Delgoffe, \{Greg M.\} and J{\'e}r{\^o}me Galon and Cesare Gridelli and Marco Merlano and Paul Nathan and Kunle Odunsi and Hideho Okada and Paulos, \{Chrystal M.\} and Sandro Pignata and Schalper, \{Kurt A.\} and Stefani Spranger and Giampaolo Tortora and Hassane Zarour and Butterfield, \{Lisa H.\} and Igor Puzanov",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = nov,

day = "29",

doi = "10.1186/s40425-019-0798-3",

language = "English",

volume = "7",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BMJ Publishing Group",

number = "1",

}

Ascierto, PA, Bifulco, C, Buonaguro, L, Emens, LA, Ferris, RL, Fox, BA, Delgoffe, GM, Galon, J, Gridelli, C, Merlano, M, Nathan, P, Odunsi, K, Okada, H, Paulos, CM, Pignata, S, Schalper, KA, Spranger, S, Tortora, G, Zarour, H, Butterfield, LH & Puzanov, I 2019, 'Perspectives in immunotherapy: Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 332. https://doi.org/10.1186/s40425-019-0798-3

TY - JOUR

T1 - Perspectives in immunotherapy

T2 - Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

AU - Ascierto, Paolo A.

AU - Bifulco, Carlo

AU - Buonaguro, Luigi

AU - Emens, Leisha A.

AU - Ferris, Robert L.

AU - Fox, Bernard A.

AU - Delgoffe, Greg M.

AU - Galon, Jérôme

AU - Gridelli, Cesare

AU - Merlano, Marco

AU - Nathan, Paul

AU - Odunsi, Kunle

AU - Okada, Hideho

AU - Paulos, Chrystal M.

AU - Pignata, Sandro

AU - Schalper, Kurt A.

AU - Spranger, Stefani

AU - Tortora, Giampaolo

AU - Zarour, Hassane

AU - Butterfield, Lisa H.

AU - Puzanov, Igor

PY - 2019/11/29

Y1 - 2019/11/29

N2 - Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.

AB - Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.

KW - Biomarkers

KW - Checkpoint inhibitors

KW - Combination therapy

KW - Immunotherapy

KW - Tumor microenvironment

UR - https://www.scopus.com/pages/publications/85075782019

U2 - 10.1186/s40425-019-0798-3

DO - 10.1186/s40425-019-0798-3

M3 - Review article

C2 - 31783779

SN - 2051-1426

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 1

M1 - 332

ER -

Perspectives in immunotherapy: Meeting report from the "immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this